Navigation Links
Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
Date:8/18/2011

ntermediate levels of HER-2 expression that are not eligible for treatment with trastuzumab (Herceptin®).  Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to the current standard of care treatment.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results may be obtained in 2012, the company opted to enroll an additional 100 patients early in 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for Herceptin.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immu
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... HILL, N.C. , June 18, 2013  Recent ... more difficult for Medical Education groups at large pharmaceutical ... on the safe and effective use of their new ... the pharma industry, it is crucial that these ... reaching healthcare professionals. To address the changes ...
(Date:6/18/2013)... , June 18, 2013  Women are frequently ... but unfortunately they often do not give the same ... have kept information from their doctor because they were ... according to a recent survey conducted by Allergan and ... dedicated to bringing education, funding and research to the ...
(Date:6/18/2013)... The board of directors of Eli Lilly ... a dividend for the third quarter of 2013 of ... The dividend is payable September 10, 2013 to ... August 15, 2013. Lilly, a leading innovation-driven ... by applying the latest research from its own worldwide ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 3New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 4New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 5New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 6New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 7New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 8New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 9
... RATE- MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE ... MEETINGSOUTH SAN FRANCISCO, Calif., March 3 Hana ... new positive preliminary efficacy results from a planned ... trial evaluating Marqibo(R) (vincristine sulfate liposomes injection) for ...
... Society of Gynecologic Oncologists (SGO) and the American College ... breast disease fellowship training program for gynecologic oncologists. ... program provides support for a gynecologic oncologist to complete ... of breast cancer and related disease. "As experts ...
Cached Medicine Technology:Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 2Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 3Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 4Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 5SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 2SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 3
(Date:6/19/2013)... June 19, 2013 Over the past ... Retailer industry has been growing at an annualized ... 2013. Many factors have supported the development of the ... retailed by drugstores; relatively higher drug prices in hospitals; ... government's support for the development of chain drug retailing ...
(Date:6/18/2013)... Chicago, IL (PRWEB) June 18, 2013 Exposed ... is helping thousands of acne suffers of all ages finally ... Unlike other acne treatment products, this new acne clearing system ... current acne, and prevent new acne from forming. ... , ExposedSkinCareReview.org believes these products are some of the most ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
(Date:6/18/2013)... Vienna, VA (PRWEB) June 18, 2013 As ... the increase in need for surgical equipment during childbirth comes ... the child from within the mother when she is unable ... difficult deliveries, they are associated with higher rates of complication ... addition to being harmful to the mother and child, forceps ...
(Date:6/18/2013)... Parker Waichman LLP , a ... victims injured by defective medical devices, reports that the ... bone graft products are now available. Published this week ... two studies serve up two key findings: There is ... and the traditional bone graft; and there is “substantial ...
Breaking Medicine News(10 mins):Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
... , DUQUESNE, Pa., Sept. 22 Wherever you live, ... house. From pulling out blankets, replacing smoke detector batteries, varying the ... their home routines in the fall. , , ... , If you are one of the estimated 40-50 ...
... INDIANAPOLIS, Sept. 22 Eli Lilly and Company (NYSE: ... Lilly China, has been promoted to president, Lilly USA, LLC. Ricks ... Business Unit as part of a company reorganization announced Sept. 14. , ... to lead Lilly USA, which is considered Lilly,s largest established market. , ...
... SALEM, N.H., Sept. 22 ALPCO is pleased ... easy and accurate measurement of both active (7-36) GLP-1 ... , , GLP-1, an incretin hormone, has been a focus ... was approved by the FDA in 2006, and early clinical data demonstrates that ...
... Results from Australia,s largest study of young drivers have shown ... roads. According to researchers from The George Institute, young drivers ... in serious crashes than those in urban areas. ... today at the launch of the Young Driver Factbase ...
... HATBORO, Pa., Sept. 22 InfoLogix, Inc. (Nasdaq: ... for the healthcare and commercial industries, announced today that it ... a private, not-for-profit healthcare system serving the greater Philadelphia area, ... large-scale Electronic Medical Record (EMR) implementation. , , ...
... , , DURHAM, N.C., Sept. 22 ... chairman and CEO, Chris Stern, will present at an investor conferences in ... will be at the Zurich Airport Radisson Hotel and is scheduled for ... be open to interested investors. , , ...
Cached Medicine News:Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 2Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 3Health News:Lilly Announces New U.S. Affiliate Leader 2Health News:ALPCO Launches GLP-1 (Active 7-36) and (7-36 and 9-36) ELISA Kits 2Health News:Rural roads dangerous for young drivers 2Health News:InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 2Health News:InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 3
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
... PY series leads are implantable bipolar ... stimulation of either the atrium or ... screw can be extended or retracted ... lead tip contains an anti-chattering mechanism ...
Used with permanent pacing leads....
Medicine Products: